|
시장보고서
상품코드
2075337
흡입제 시장 : 약물 계열별, 제품 유형별, 용도별, 유통 채널별, 지역별Global Inhalable Drugs Market, By Drug Class, By Product Type, By Application, By Distribution Channel, By Region |
||||||
세계의 흡입제 시장은 2026년에 430억 2,000만 달러 규모에 달할 것으로 추정되며, 2033년까지 709억 2,000만 달러에 달할 것으로 예상됩니다. 2026년부터 2033년까지 CAGR 7.4%로 성장할 것으로 전망됩니다.
| 보고서 범위 | 보고서 상세 | ||
|---|---|---|---|
| 기준 연도: | 2025년 | 2026년 시장 규모: | 430억 2,000만 달러 |
| 과거 데이터 기간: | 2020-2024년 | 예측 기간: | 2026-2033년 |
| 2026년부터 2033년까지 예측 기간의 CAGR: | 7.40% | 2033년 시장 규모 예측: | 709억 2,000만 달러 |
흡입제는 호흡기를 통해 폐에 국소적으로 투여되어 신속한 치료 효과를 가져오는 의약품입니다. 이 약들은 천식, 만성 폐쇄성 폐질환(COPD), 낭포성섬유증 등의 폐 질환 치료에 특히 효과적입니다. 폐는 소화관을 통해 경구 투여하는 경우와 비교했을 때, 약물 흡수를 위한 매우 넓은 표면적을 제공합니다. 흡입제는 간에서의 첫 통과 대사를 피함으로써 약물을 폐 조직에 직접적이고 신속하게 전달할 수 있어, 전신 내 약물 농도가 낮아집니다. 주요 장점으로는 경구용 약물과 비교해 수 분 이내에 효과가 나타나기 시작한다는 점, 투여량이 적다는 점, 부작용이 적다는 점 등을 들 수 있습니다. 대표적인 흡입제에는 천식이나 만성 폐쇄성 폐질환(COPD)에 사용되는 기관지확장제(알부테롤 등), 코르티코스테로이드, 분산성 항생제, 인슐린 등이 있습니다. 전 세계적으로 폐 질환이 증가하고 있는 만큼, 흡입제 시장은 앞으로도 꾸준히 성장할 것으로 예상됩니다.
시장 역학:
세계 흡입제 시장은 전 세계적으로 천식이나 COPD(만성 폐쇄성 폐질환) 등 호흡기질환의 유병률이 증가하고 있는 추세에 힘입어 성장하고 있습니다. 예를 들어, 2023년 3월 16일 기준 세계보건기구(WHO) 보고서에 따르면, 만성 폐쇄성 폐질환(COPD)은 전 세계 사망 원인 중 3위를 차지하고 있으며, 2021년에는 3억 명 이상이 천식으로 고통받고 있고, 매년 300만 명 이상이 COPD로 사망하고 있습니다. 대기 오염의 악화와 생활 방식의 변화가 폐 질환 환자 수 증가의 한 원인이 되고 있습니다. 또한, 기도에 직접 작용하는 질환의 치료에 있어 흡입제가 뛰어난 치료 효과를 발휘하는 점도 시장 성장에 기여하고 있습니다. 정량 분무식 흡입기(MDI)나 건조 분말 흡입기(DPI)와 같은 약물전달 기기의 기술적 진보로 인해, 새로운 치료법의 성장 기회가 확대되고 있습니다. 그러나 흡입제 개발 및 제조에 따르는 높은 비용이 시장의 추가적인 성장을 제한하고 있습니다. 그 밖의 제약으로는 폐용 약물전달 시스템에 관한 임상시험 및 제품 승인을 둘러싼 엄격한 규제가 있습니다. 그렇긴 하지만, 첨단 제제 및 병용요법에 대한 지속적인 연구 개발(R&D)을 통해 예측 기간 동안 새로운 길이 열릴 가능성이 있습니다.
본 조사의 주요 특징:
- 본 조사에서는 다양한 부문의 잠재적 수익 기회를 파악하고, 이 시장에서 매력적인 투자 제안 매트릭스에 대해 설명하고 있습니다.
- 또한, 본 조사에서는 시장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 그리고 주요 기업들이 채택하는 경쟁 전략에 관한 중요한 인사이트를 제공합니다.
- 본 조사에서는 다음의 파라미터(기업 개요, 제품 포트폴리오, 주요 하이라이트, 재무 실적, 전략)를 바탕으로 전 세계 흡입제 시장의 주요 기업 개요을 소개하고 있습니다.
- 이 보고서를 통해 얻은 인사이트를 바탕으로, 기업의 마케팅 담당자 및 경영진은 향후 제품 출시, 제품 유형 업그레이드, 시장 확대 및 마케팅 전략에 대해 정보에 입각한 의사결정을 내릴 수 있게 됩니다.
- 세계 흡입제 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진입 기업, 금융 애널리스트 등 이 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자 여러분은 전 세계 흡입제 시장 분석에 활용되는 다양한 전략 매트릭스를 활용함으로써 의사결정을 원활하게 진행할 수 있을 것입니다.
목차
제1장 조사 목적과 가정
제2장 시장 전망
제3장 시장 역학·규제·동향 분석
제4장 세계의 흡입제 시장 : 약물 계열별, 2021-2033년
제5장 세계의 흡입제 시장 : 제품 유형별, 2021-2033년
제6장 세계의 흡입제 시장 : 용도별, 2021-2033년
제7장 세계의 흡입제 시장 : 유통 채널별, 2021-2033년
제8장 세계의 흡입제 시장 : 지역별, 2021-2033년
제9장 경쟁 구도
제10장 섹션
KSM 26.07.09Global Inhalable Drugs Market is estimated to be valued at USD 43.02 Bn in 2026 and is expected to reach USD 70.92 Bn by 2033, growing at a compound annual growth rate (CAGR) of 7.4% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 43.02 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 7.40% | 2033 Value Projection: | USD 70.92 Bn |
Inhalable drugs are medical substances that can be administered locally through the respiratory tract via the lung for rapid therapeutic effects. They are particularly effective for treating lung conditions such as asthma, chronic obstructive pulmonary disease and cystic fibrosis. The lung provides huge surface area for drug absorption as compared to oral administration through the gastrointestinal tract. Inhalable drugs bypass hepatic first-pass metabolism for faster delivery of medications directly to the lung tissues and lower systemic levels. Some key advantages include rapid onset of action within minutes, lower dosing, and reduced side effects as compared to oral medications. Popular inhalable drugs include bronchodilators for asthma and chronic obstructive pulmonary disease like albuterol, corticosteroids, dispersible antibiotics, and insulin. With rising lung diseases globally, the inhalable drugs market is expected to grow steadily in the future.
Market Dynamics:
Global inhalable drugs market is driven by the growing prevalence of respiratory diseases such as asthma and COPD worldwide. For instance, on March 16, 2023, according to the World Health Organization (WHO), chronic obstructive pulmonary disease (COPD) is the third leading cause of death worldwide, and over 300 Mn people suffered from asthma in 2021, while over 3 Mn people die each year from COPD. Increasing pollution levels and changing lifestyles have contributed to the rising caseload of lung illnesses. The market also benefits from the superior therapeutic efficacy of inhalable drugs in treating conditions, affecting the respiratory tract directly. Technological advancements in drug delivery devices such as metered-dose inhalers (MDIs) and dry powder inhalers (DPIs) are expanding opportunities for novel therapies. However, high costs that are associated with development and production of inhalable drugs limit wider market growth. Additional constraints include stringent regulations around clinical trials and product approval for pulmonary drug delivery systems. Nevertheless, ongoing research and development (R&D) into advanced formulations and combination therapies could unlock new avenues over the forecast period.
Key features of the study:
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global inhalable drugs market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include GSK plc, Mundipharma International., Boehringer Ingelheim International GmbH., Cipla Inc., AstraZeneca, Sanofi, Vectura Group Ltd, Viatris Inc, 3M Health Care, Allied Healthcare Products, Inc., CareFusion Corporation, GF Health Products, Inc., Merck & Co., Inc., Novartis AG, Omron Healthcare, Inc., Glenmark Pharmaceuticals and PARI Respiratory Equipment, Inc.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- Global inhalable drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global inhalable drugs market
Detailed Segmentation:
- Global Inhalable Drugs Market, By Drug Class (Revenue, USD Bn, 2021 - 2033)
- Inhaled Corticosteroids
- Leukotriene modifiers
- Long-acting beta agonists (LABAs)
- Long-acting muscarinic antagonists (LAMAs)
- Others
- Global Inhalable Drugs Market, By Product Type (Revenue, USD Bn, 2021 - 2033)
- Aerosol
- Dry powder Formulation
- Spray
- Others
- Global Inhalable Drugs Market, By Application (Revenue, USD Bn, 2021 - 2033)
- Respiratory Diseases
- Asthma
- Chronic Obstructive Pulmonary Disease (COPD)
- Cystic Fibrosis
- Allergic Rhinitis
- Others
- Non-respiratory Disease
- Global Inhalable Drugs Market, By Distribution Channel (Revenue, USD Bn, 2021 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Regional Insights (Revenue, USD Bn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Top Companies in the Global Inhalable Drugs Market:
- GSK plc.
- Mundipharma International.
- Boehringer Ingelheim International GmbH.
- Cipla Inc.
- AstraZeneca
- Sanofi
- Vectura Group Ltd.
- Viatris Inc.
- 3M Health Care
- Allied Healthcare Products, Inc.
- CareFusion Corporation
- GF Health Products, Inc.
- Merck & Co., Inc.
- Novartis AG
- Omron Healthcare, Inc.
- Glenmark Pharmaceuticals
- PARI Respiratory Equipment, Inc.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Inhalable Drugs Market, By Drug Class
- Global Inhalable Drugs Market, By Product Type
- Global Inhalable Drugs Market, By Application
- Global Inhalable Drugs Market, By Distribution Channel
- Global Inhalable Drugs Market, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Growing prevalence of respiratory diseases
- Risk of misuse of inhalable medicines
- Emergence of new drug delivery technologies
- Key Highlights
- Regulatory Scenario
- Recent Trends
- PEST Analysis
- PORTER's Analysis
- Mergers, Acquisitions, and Collaborations
4. Global Inhalable Drugs Market, By Drug Class, 2021 - 2033, (US$ Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Inhaled Corticosteroids
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
- Leukotriene modifiers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
- Long-acting beta antagonists (LABAs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
- Long-acting muscarinic antagonists (LAMAs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
5. Global Inhalable Drugs Market, By Product Type, 2021 - 2033, (US$ Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Aerosol
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
- Dry powder Formulation
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
- Spray
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
6. Global Inhalable Drugs Market, By Application, 2021 - 2033, (US$ Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Respiratory Diseases
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
- Asthma
- Chronic Obstructive Pulmonary Disease (COPD)
- Cystic Fibrosis
- Allergic Rhinitis
- Others
- Non-respiratory Disease
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
7. Global Inhalable Drugs Market, By Distribution Channel, 2021 - 2033, (US$ Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
8. Global Inhalable Drugs Market, By Region, 2021 - 2033, (US$ Bn)
- Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Region, 2022 -2033
- Country Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033,(US$ Bn)
- U.S.
- Canada
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033,(US$ Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033,(US$ Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033,(US$ Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033,(US$ Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2021 - 2033,(US$ Bn)
- North Africa
- Central Africa
- South Africa
9. Competitive Landscape
- Company Profile
- GSK plc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Mundipharma International.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Boehringer Ingelheim International GmbH.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Cipla Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- AstraZeneca
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Sanofi
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Strategies
- Vectura Group Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Viatris Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- 3M Health Care
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Allied Healthcare Products, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- CareFusion Corporation
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- GF Health Products, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Merck & Co., Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Omron Healthcare, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Glenmark Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- PARI Respiratory Equipment, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- GSK plc.
- Analyst Views
10. Section
- Reference
- Research Methodology
- About us
